文献速递哮喘

维生素D补充对维生素D缺乏哮喘患者哮喘控制的影响:ACVID随机临床试验

Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial.
PubMed 文献 · Thorax · 2020-11-05

ACVID为随机、三盲、安慰剂对照平行组试验,纳入血清25-羟基维生素D3<30 ng/mL的成人哮喘患者112例,干预组每周口服16 000 IU骨化二醇,对照组加用安慰剂,疗程6个月。结果显示干预组ACT评分改善+3.09,对照组-0.57,差值3.66(95%CI 0.89至5.43;p<0.001),生活质量亦显著改善。

要点

  • 维生素D缺乏的成人哮喘患者每周口服16 000 IU骨化二醇6个月可改善哮喘控制。
  • 干预组ACT评分改善+3.09,对照组-0.57,组间差值3.66(95%CI 0.89至5.43;p<0.001)。
  • 生活质量(mini AQLQ)干预组改善5.34,对照组4.64,差值0.7(95%CI 0.15至1.25;p=0.01)。

核心结论

  • 在维生素D缺乏的成人哮喘患者中,与安慰剂相比,每周口服骨化二醇补充6个月可改善哮喘控制。
  • 需要进一步研究评估长期疗效和安全性。

研究设计与样本

  • 随机、三盲、安慰剂对照、平行组研究。
  • 纳入血清25-羟基维生素D3<30 ng/mL的成人哮喘患者。
  • 共随机112例(平均年龄55岁,87例(78%)为女性),106例(95%)完成试验。
  • 干预组56例每周口服16 000 IU骨化二醇,对照组56例在常规哮喘治疗基础上加用安慰剂,研究周期6个月。

主要发现

  • 主要终点ACT评分:干预组改善+3.09,对照组-0.57,差值3.66(95%CI 0.89至5.43;p<0.001)。
  • 次要终点生活质量(mini AQLQ):干预组改善5.34,对照组4.64,差值0.7(95%CI 0.15至1.25;p=0.01)。

关键数值与推荐

  • 纳入标准:成人哮喘患者,血清25-羟基维生素D3<30 ng/mL。
  • 干预方案:每周口服16 000 IU骨化二醇,疗程6个月。
  • 主要终点:采用哮喘控制测试(ACT)评估的哮喘控制程度。

临床怎么用

  • 对维生素D缺乏的成人哮喘患者,可考虑每周口服16 000 IU骨化二醇补充6个月以改善哮喘控制和生活质量。
  • 长期疗效与安全性尚需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between asthma and vitamin D deficiency has been known for some time. However, interventional studies conducted in this regard have shown conflicting results. OBJECTIVE: To evaluate the efficacy of vitamin D supplementation in asthmatic patients in improving the degree of control of asthma. METHODS: Randomised, triple-blind, placebo-controlled, parallel-group study in adult asthmatic patients with serum 25-hydroxyvitamin-D3 <30 ng/mL. The intervention group received oral supplementation with 16 000 IU of calcifediol per week, and the control group had placebo added to their usual asthma treatment. The study period was 6 months. The primary endpoint was the degree of asthma control as determined by the asthma control test (ACT). Secondary endpoints included quality of life measured using the mini Asthma Quality of Life Questionnaire, the number of asthma attacks, oral corticosteroid cycles, the dose of inhaled corticosteroids, number of emergency visits, unscheduled consultations with the primary care physician and hospitalisations for asthma. RESULTS: One hundred and twelve patients were randomised (mean age 55 years, with 87 (78%) being women). Of the 112 patients, 106 (95%) completed the trial. Half the patients (56) were assigned to the intervention group and the other half to the control group. A statistically significant clinical improvement was observed in the intervention group (+3.09) compared with the control group (-0.57) (difference 3.66 (95% CI 0.89 to 5.43); p<0.001) as measured using ACT scores. Among the secondary endpoints, a significant improvement in the quality of life was found in the intervention group (5.34), compared with the control group (4.64) (difference 0.7 (95% CI 0.15 to 1.25); p=0.01). CONCLUSION: Among adults with asthma and vitamin D deficiency, supplementation with weekly oral calcifediol compared with placebo improved asthma control over 6 months. Further research is needed to assess long-term efficacy and safety. TRIAL REGISTRATION NUMBER: NCT02805907.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Andújar-Espinosa R, Salinero-González L, Illán-Gómez F, et al. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. Thorax. 2020. PMID: 33154023. doi:10.1136/thoraxjnl-2019-213936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。